Teva announces agreement on generic Pulmicort Respules patent challenge



Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer. This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree

Full Post: Breast cancer four times more likely in women with strong family history

Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva’s U.S. generic version of AstraZeneca’s Pulmicort (Budesonide) Respules including all claims for patent infringement and damages.

Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S. sales of its generic budesonide respules and provides that any product already shipped by Teva will remain in the market to be further distributed and dispensed. Teva will not resume shipping additional units of its budesonide respules until December 15, 2009 (or earlier based on certain contingencies) pursuant to an exclusive license for which Teva will pay AstraZeneca an undisclosed royalty.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world’s leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva’s sales are in North America and Europe.

http://www.tevapharm.com/

Link




AstraZeneca has announced it has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA. The agreement settles the patent infringement litigation filed by AstraZeneca following Teva’s submission to the United States Food & Drug Administration of an Abbreviated New Drug

Full Post: AstraZeneca settles U.S. Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals



Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United

Full Post: Codexis announces licensing agreement with Teva Pharmaceutical Industries



Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that they received approval from the European Commission to proceed with Teva’s acquisition of Barr. In connection with this approval, Teva and Barr are required to divest certain formulations of 17 generic drugs in certain specific countries with respect to which they have a product

Full Post: Teva and Barr receive European approval for acquisition



Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc. has entered into separate settlement agreements related to ongoing patent challenges for Nasacort AQ (triamcinolone acetonide) nasal spray, Allegra D-12 Hour (fexofenadine hydrochloride 60mg and pseudoephedrine hydrochloride 120mg) extended-release tablets, and Allegra (fexofenadine) 30mg, 60mg and 180mg tablets. As part of the settlements, the

Full Post: Barr announces agreements on Nasacort AQ, Allegra D-12 and Allegra patent challenges



Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that the U.S. Federal Trade Commission (”FTC”) has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period. Under the consent order that has been executed by the parties

Full Post: Teva’s acquisition of Barr cleared by FTC